#CMSC16 – Fingolimod (Gilenya) Offers Consistent Health Benefits in Relapsing-Remitting MS Patients
News
Researchers at the Swedish Neuroscience Institute in Washington and Novartis Pharma revealed that Gilenya (fingolimod) induced a consistent and significant reduction in disease activity in patients with relapsing-remitting ... Read more